Lupin announced the launch of DIFIZMA to treat inadequately controlled asthma

Gobal pharma major Lupin Limited has announced the launch of a novel fixed-dose triple drug combination (FDC) of Indacaterol, Glycopyrronium and Mometasone, under the brand name DIFIZMA in India, for managing inadequately controlled asthma among patients by improving lung function, providing better symptom control and reducing exacerbations.

DIFIZMA is the only FDC dry powder inhalation (DPI) product combining Indacaterol, a long-acting beta-agonist, Glycopyrronium, a long-acting muscarinic receptor antagonist, and Mometasone Furoate, an inhaled corticosteroid, that has been approved by the Drug Controller General of India (DCGI) for the treatment of inadequately controlled asthma. The drug will be available in one strength with a fixed dose to be taken once daily. Commenting on the launch, Rajeev Sibal, President, India Region Formulations, Lupin said, “DIFIZMA is aimed at catering to the unmet need of patients with inadequately controlled asthma and aligns closely with Lupin’s ideology of patient-centricity and enabling accessibility for medicines.”